连氨基脲链的三氮唑并噻二唑类DOT1L抑制剂的设计、合成及活性

doi:10.6023/cjoc201910037

有机化学 ›› 2020, Vol. 40 ›› Issue (8): 2450-2459.DOI: 10.6023/cjoc201910037 上一篇下一篇

研究论文

连氨基脲链的三氮唑并噻二唑类DOT1L抑制剂的设计、合成及活性

刘娜^a, 郭思岐^b,c, 刘俊芳^a, 陈彦韬^b, 徐晓明^a, 张静^a, 康亚青^a, 罗成^b, 陈示洁^b, 陈华^a

a 河北大学化学与环境科学学院河北省化学生物学重点实验室河北保定 071002;
b 中国科学院上海药物研究所新药研究国家重点实验室上海 201203;
c 南昌大学药学院南昌 330006

收稿日期:2019-10-29 修回日期:2020-01-13 发布日期:2020-05-28
通讯作者: 陈示洁, 陈华 E-mail:shijiechen@simm.ac.cn;hua-todd@163.com
基金资助:
河北大学自然科学多学科交叉研究计划（No.DXK201903）资助项目.

Design, Synthesis, and Biological Activities of Novel Triazolothiadiazole Derivatives Linked with Amino Side Chain Containing Urea Group as DOT1L Inhibitors

Liu Na^a, Guo Siqi^b,c, Liu Junfang^a, Chen Yantao^b, Xu Xiaoming^a, Zhang Jing^a, Kang Yaqing^a, Luo Cheng^b, Chen Shijie^b, Chen Hua^a

a Key Laboratory of Chemical Biology of Hebei Province, College of Chemistry and Environmental Science, Hebei University, Baoding, Hebei 071002;
b State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Science, Shanghai 201203;
c School of Pharmacy, Nanchang University, Nanchang 330006

Received:2019-10-29 Revised:2020-01-13 Published:2020-05-28
Supported by:
Project supported by the Natural Science Interdisciplinary Research Program of Hebei University (No. DXK201903).

文章分享

1. cjoc201910037辅助材料.pdf(4676KB)

摘要/Abstract

依据优势片段结合的药物设计方法，设计了新的连接有氨基脲链的三氮唑并噻二唑类DOT1L（类端粒沉默干扰体1）酶抑制剂.化合物的合成以芳香酸为原料，经五步反应得到了含苄基氯结构的三氮唑并噻二唑中间体13.弱碱性（DIPEA）条件下，化合物13与氨基侧链发生亲核取代反应，得到连氨基脲链的三氮唑并噻二唑类化合物15a~15k；而在强碱性（NaH）条件下，化合物13自身反应得到新的三氮唑并噻二唑连三氮唑并噻二嗪的二聚结构类似物22a~22d.测试了化合物15和22对DOT1L的酶抑制活性，结果显示所测化合物在50 μmol·L^-1时表现出中等或较弱的DOT1L抑制活性，其中化合物15k和二聚类似物22a活性最好，IC₅₀值分别为25.92和10.59μmol·L^-1，但均低于阳性对照物（E）-6-（2-（呋喃-2-基）乙烯基）-3-苯基-[1，2，4]三唑[3，4-b][1，3，4]噻二唑的酶抑制活性.分子对接实验提示，氨基脲侧链体积较大，可能是所合成化合物活性较低的主要原因.

关键词: DOT1L抑制剂, 三氮唑并噻二唑, 三氮唑并噻二嗪, 亲核取代

Based on the drug design method of combination of privileged fragments, a series of novel triazolothiadiazole derivatives linked with amino side chain containing urea group were designed as potential DOT1L (disruptor of telomeric silencing 1-like) inhibitors. The intermediate 13 with benzyl chloride on triazolothiadiazole structure was synthesized from aromatic acid through five steps. Under the condition of weak base (DIPEA), the nucleophilic substitution reaction between 13 and amino chain with urea group resulted in triazolothiadiazole derivatives linked with amino side chain containing urea group 15a~15k, while under the condition of strong base (NaH), the new dimeric structure analogues 22a~22d bearing with triazolothiadiazole-triazolothiadiazine were obtained by intermolecular reaction of two molecules of 13. The inhibitory activities of compounds 15 and 22 against DOT1L were tested. The results showed that the tested compounds exhibited moderate or weak DOT1L inhibitory activities at 50 μmol·L^-1. Among them, compounds 15k and 22a were the best ones with IC₅₀ values of 25.92 and 10.59 μmol·L^-1, respectively, lower than that of the positive control (E)-6-(2-(furan-2-yl)vinyl)-3-phenyl-[1,2, 4]triazolo[3,4-b] [1,3,4]thiadiazole (10). The results of docking experiments suggested that the bulky amino-urea side chain might be the main reason for the loss of the activities of the compounds, which sterically hindered the molecular from binding to the DOT1L enzyme.

Key words: DOT1L inhibitor, triazolothiadiazole, triazolothiadiazine, nucleophilic substitution

引用此文

刘娜, 郭思岐, 刘俊芳, 陈彦韬, 徐晓明, 张静, 康亚青, 罗成, 陈示洁, 陈华. 连氨基脲链的三氮唑并噻二唑类DOT1L抑制剂的设计、合成及活性[J]. 有机化学, 2020, 40(8): 2450-2459.

Liu Na, Guo Siqi, Liu Junfang, Chen Yantao, Xu Xiaoming, Zhang Jing, Kang Yaqing, Luo Cheng, Chen Shijie, Chen Hua. Design, Synthesis, and Biological Activities of Novel Triazolothiadiazole Derivatives Linked with Amino Side Chain Containing Urea Group as DOT1L Inhibitors[J]. Chinese Journal of Organic Chemistry, 2020, 40(8): 2450-2459.

导出引用 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

分享此文

参考文献

[1] Min, J. R.; Feng, Q.; Li, Z. Z.; Zhang, Y.; Xu, R. M. Cell 2003, 112, 711.
[2] Kim, W.; Choi, M.; Kim, J. E. Cell Cycle 2014, 13, 726.
[3] Bernt, K. M.; Zhu, N.; Sinha, A. U.; Vempati, S.; Faber, J.; Krivtsov, A. V.; Feng, Z.; Punt, N.; Daigle, A.; Bullinger, L.; Pollock, R. M.; Richon, V. M.; Kung, A. L.; Armstrong, S. A. Cancer Cell 2011, 20, 66.
[4] Lillico, R.; Lawrence, C. K. Lakowski, T. M. J. Proteome Res. 2018, 17, 2657.
[5] Anglin, J. L.; Song, Y. J. Med. Chem. 2013, 56, 8972.
[6] Zhou, S. H.; Sun, P. J.; Zhao, Y. Q.; Zhang, Y.; Yu, N. F. Acta Pharm. Sin. 2018, 53, 500(in Chinese). (周仕海, 孙朋举, 赵勇强, 张岩, 余聂芳, 药学学报, 2018, 53, 500.)
[7] Ümit Kaniskan, H.; Martini, M. L.; Jin, J. Chem. Rev. 2018, 118, 989.
[8] Basavapathruni, A.; Jin, L.; Daigle, S. R.; Majer, C. R.; Therkelsen, C. A.; Wigle, T. J.; Kuntz, K. W.; Chesworth, R.; Pollock, R. M.; Scott, M. P. Moyer, M. P.; Richon, V. M.; Copeland, R. A.; Olhava, E. J. Chem. Biol. Drug Des. 2012, 80, 971.
[9] Daigle, S. R.; Olhava, E. J.; Therkelsen, C. A.; Majer, C. R.; Sneeringer, C. J.; Song, J.; Johnston, L. D.; Scott, M. P.; Smith, J. J.; Xiao, Y.; Jin, L.; Kuntz, K. W.; Chesworth, R.; Moyer, M. P.; Bernt, K. M.; Tseng, J. C.; Kung, A. L.; Copeland, R. A.; Richon, V. M.; Pollock, R. M. Cancer Cell 2011, 20, 53.
[10] Stein, E. M.; Garcia-Manero, G.; Rizzieri, D. A.; Savona, M.; Tibes, R.; Altman, J. K.; Jongen-Lavrencic, M.; Dohner, H.; Armstrong, S.; Pollock, R. M.; Waters, N. J.; Legler, M.; Thomson, B.; Daigle, S.; McDonald, A.; Campbell, C.; Olhava, E.; Hedrick, E. E.; Lowenberg, B.; Copeland, R. A.; Tallman, M. S. Blood 2014, 124, 387.
[11] Yao, Y.; Chen, P.; Diao, J.; Cheng, G.; Deng, L.; Anglin, J. L.; Prasad, B. V.; Song, Y. J. Am. Chem. Soc. 2011, 133, 16746.
[12] Anglin, J. L.; Deng, L.; Yao, Y.; Cai, G.; Liu, Z.; Jiang, H.; Cheng, G.; Chen, P.; Dong, S.; Song, Y. J. Med. Chem. 2012, 55, 8066.
[13] Yu, W.; Chory, E. J.; Wernimont, A. K.; Tempel, W.; Scopton, A.; Federation, A.; Marineau, J. J.; Qi, J.; Barsyte-Lovejoy, D.; Yi, J.; Marcellus, R.; Iacob, R. E.; Engen, J. R.; Griffin, C.; Aman, A.; Wienholds, E.; Li, F.; Pineda, J.; Estiu, G.; Shatseva, T.; Hajian, T.; Al-Awar, R.; Dick, J. E.; Vedadi, M.; Brown, P. J.; Arrowsmith, C. H.; Bradner, J. E.; Schapira, M. Nat. Commun. 2012, 3, 1288.
[14] Yu, W.; Smil, D.; Li, F.; Tempel, W.; Fedorov, O.; Nguyen, K. T.; Bolshan, Y.; Al-Awar, R.; Knapp, S.; Arrowsmith, C. H.; Vedadi, M.; Brown, P. J.; Schapira, M. Bioorg. Med. Chem. 2013, 21, 1787.
[15] Spurr, S. S.; Bayle, E. D.; Yu, W. Y.; Li, F. L.; Tempel, W.; Vedadi, M.; Schapira, M.; Fish, P. V. Bioorg. Med. Chem. Lett. 2016, 26, 4518.
[16] Chen, J.; Park, H. J. ACS Chem. Biol. 2019, 14, 873.
[17] Scheufler, C.; Möbitz, H.; Gaul, C.; Ragot, C.; Be, C.; Fernández, C.; Beyer, K. M.; Tiedt, R.; Stauffer, F. ACS Med. Chem. Lett. 2016, 7, 730.
[18] Chao, C.; Zhu, H.; Stauffer, F.; Caravatti, G.; Vollmer, S.; Machauer, R.; Holzer, P.; Möbitz, H.; Scheufler, C.; Klumpp, M.; Tiedt, R.; Beyer, K. S.; Calkins, K.; Guthy, D.; Kiffe, M.; Zhang, J.; Gaul, C. ACS Med. Chem. Lett. 2016, 7, 735.
[19] Möbitz, H.; Machauer, R.; Holzer, P.; Vaupel, A.; Stauffer, F.; Ragot, C.; Caravatti, G.; Scheufler, C.; Fernández, C.; Hommel, U.; Tiedt, R.; Beyer, K. S.; Chao, C.; Zhu, H.; Gaul, C. ACS Med. Chem. Lett. 2017, 8, 338.
[20] Chen, S. J.; Wang, Y. L.; Zhou, W.; Li, S. S.; Peng, J. L.; Shi, Z.; Hu, J. C.; Liu, Y. C.; Ding, H.; Lin, Y. Y.; Li, L. J.; Cheng, S. F.; Liu, J. Q.; Lu, T.; Jiang, H. L.; Liu, B.; Zheng, M. Y.; Luo, C. J. Med. Chem. 2014, 57, 9028.
[21] Chen, S.; Li, L.; Chen, Y.; Hu, J.; Liu, J.; Liu, Y. C.; Liu, R.; Zhang, Y.; Meng, F.; Zhu, K.; Lu, J.; Zheng, M.; Chen, K.; Zhang, J.; Jiang, H.; Yao, Z.; Luo, C. J. Chem. Inf. Model. 2016, 56, 527.
[22] Wang, Y. L.; Li, L. J.; Zhang, B. D.; Xing, J.; Chen, S. J.; Wan, W.; Song, Y. K.; Jiang, H.; Jiang, H. L.; Luo, C.; Zheng, M. Y. J. Med. Chem. 2017, 60, 2026.
[23] Song, Y. K.; Li, L. J.; Chen, Y. T.; Liu, J. Q.; Xiao, S. H.; Lian, F. L.; Zhang, N. X.; Ding, H.; Zhang, Y. Y.; Chen, K. X.; Jiang, H. L.; Zhang, C. H.; Liu, Y. C.; Chen, S. J.; Luo, C. Bioorg. Med. Chem. 2018, 26, 1751.
[24] Zhang, L.; Chen, Y. T.; Liu, N.; Li, L. J.; Xiao, S. H.; Li, X. L.; Chen, K. X.; Luo, C.; Chen, S. J.; Chen, H. Bioorg. Chem. 2018, 80, 649.
[25] Cui, P. L.; Li, X. L.; Zhu, M. Y.; Wang, B. H.; Liu, J.; Chen, H. Eur. J. Med. Chem. 2017, 127, 159.
[26] Maestro, Version 10.4, Schrödinger, LLC, New York, 2015.
[27] Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. J. Med. Chem. 2004, 47, 1739.
[28] Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. J. Med. Chem. 2006, 49, 6177.
[29] Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Thomas Pollard, W.; Banks, J. L. J. Med. Chem. 2004, 47, 1750.
[30] Glide, Version 6.9, Schrödinger, LLC, New York, 2015.

连氨基脲链的三氮唑并噻二唑类DOT1L抑制剂的设计、合成及活性

Design, Synthesis, and Biological Activities of Novel Triazolothiadiazole Derivatives Linked with Amino Side Chain Containing Urea Group as DOT1L Inhibitors

PDF

补充材料

可视化

摘要/Abstract

引用此文

分享此文

参考文献

相关文章 15

编辑推荐

相关统计

本文评价

[1]	张勇, 田志高, 黄琳, 侯秋飞, 范红红, 汪万强. α-氰醇甲磺酸酯在合成α-氨基腈类化合物中的应用[J]. 有机化学, 2024, 44(2): 561-572.
[2]	黄志友, 杨平, 何波, 欧文霞, 袁思雨. 吗啉磺酰胺化合物的设计、合成及其抑制大豆萌芽活性的研究[J]. 有机化学, 2024, 44(1): 309-315.
[3]	王雷刚, 郑逸轩, 周希, 王海峰, 严琼姣, 汪伟, 陈芬儿. α-氰醇甲磺酸酯与丙二酸酯的亲核取代反应合成α-芳基腈类化合物[J]. 有机化学, 2023, 43(2): 668-678.
[4]	朱源, 陈乐园, 侯文彬, 李祎亮. 亲核氟源参与的芳环氟-18标记反应研究进展[J]. 有机化学, 2021, 41(5): 1774-1788.
[5]	王霞, 屈益欣, 龙城宇, 王雪强. 杂芳基烷基醚、杂芳基卤化物与(氘代)醇的亲核醚化[J]. 有机化学, 2021, 41(2): 795-805.
[6]	李鑫玲, 刘会丽, 张顺吉. 炔丙醇与烯醇硅醚的直接亲核取代反应[J]. 有机化学, 2021, 41(1): 407-411.
[7]	李若馨, 韩锐, 高锦明. 鸟巢烷二萜关键中间体的合成[J]. 有机化学, 2020, 40(7): 2148-2152.
[8]	赵转霞, 王君姣, 黄丹凤, 杨政, 赵芳霞, 虎永琴, 徐炜刚, 胡雨来. 锡粉促进下3-芳基-3-羟基-2-氧化吲哚的烯丙基化反应研究[J]. 有机化学, 2020, 40(7): 2026-2034.
[9]	张顺吉, 刘会丽. 硫酸催化的炔丙醇快速亲核取代反应[J]. 有机化学, 2020, 40(5): 1257-1265.
[10]	徐晓明, 郭思岐, 张静, 陈彦韬, 康亚青, 刘娜, 刘俊芳, 罗成, 陈示洁, 陈华. 三氮唑并噻二唑类DOT1L抑制剂的结构修饰及活性[J]. 有机化学, 2020, 40(5): 1345-1354.
[11]	韩满意, 潘虹, 姚紫云, 李琦. 四丁基溴化铵催化的布鲁克重排/烷基化反应[J]. 有机化学, 2020, 40(12): 4274-4283.
[12]	田禾, 吴景卫, 刘钰强, 谢亚非, 王建武, 赵桂龙. 含烷氧基取代的三唑类结构的尿酸转运体1抑制剂的高效合成方法[J]. 有机化学, 2017, 37(7): 1748-1756.
[13]	张小祥, 吕昌, 李萍, 付博, 姚薇薇. Lewis/Brønsted酸催化炔丙醇在亲核取代反应中的研究进展[J]. 有机化学, 2016, 36(6): 1287-1298.
[14]	孙志东, 朱云龙, 黄海洋, 宋贤荣, 肖强. L-胞嘧啶异核苷的全合成研究[J]. 有机化学, 2016, 36(11): 2729-2734.
[15]	张小祥, 孙小萍, 谈继淮, 樊辉, 饶卫东. 烯丙醇在亲核取代反应中的研究进展[J]. 有机化学, 2015, 35(10): 2049-2058.